Literature DB >> 26074157

Design and properties of novel gallium-doped injectable apatitic cements.

Charlotte Mellier1, Franck Fayon2, Florian Boukhechba1, Elise Verron3, Myriam LeFerrec1, Gilles Montavon4, Julie Lesoeur3, Verena Schnitzler1, Dominique Massiot2, Pascal Janvier5, Olivier Gauthier3, Jean-Michel Bouler6, Bruno Bujoli5.   

Abstract

Different possible options were investigated to combine an apatitic calcium phosphate cement with gallium ions, known as bone resorption inhibitors. Gallium can be either chemisorbed onto calcium-deficient apatite or inserted in the structure of β-tricalcium phosphate, and addition of these gallium-doped components into the cement formulation did not significantly affect the main properties of the biomaterial, in terms of injectability and setting time. Under in vitro conditions, the amount of gallium released from the resulting cement pellets was found to be low, but increased in the presence of osteoclastic cells. When implanted in rabbit bone critical defects, a remodeling process of the gallium-doped implant started and an excellent bone interface was observed. STATEMENT OF SIGNIFICANCE: The integration of drugs and materials is a growing force in the medical industry. The incorporation of pharmaceutical products not only promises to expand the therapeutic scope of biomaterials technology but to design a new generation of true combination products whose therapeutic value stem equally from both the structural attributes of the material and the intrinsic therapy of the drug. In this context, for the first time an injectable calcium phosphate cement containing gallium was designed with properties suitable for practical application as a local delivery system, implantable by minimally invasive surgery. This important and original paper reports the design and in-depth chemical and physical characterization of this groundbreaking technology.
Copyright © 2015 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Biocompatibility; Calcium phosphate cements; Design; Gallium; Handling properties

Mesh:

Substances:

Year:  2015        PMID: 26074157     DOI: 10.1016/j.actbio.2015.05.027

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  6 in total

1.  Biocompatible nano-gallium/hydroxyapatite nanocomposite with antimicrobial activity.

Authors:  Mario Kurtjak; Marija Vukomanović; Lovro Kramer; Danilo Suvorov
Journal:  J Mater Sci Mater Med       Date:  2016-10-04       Impact factor: 3.896

2.  Solid-state 31P and 1H chemical MR micro-imaging of hard tissues and biomaterials with magic angle spinning at very high magnetic field.

Authors:  Maxime Yon; Vincent Sarou-Kanian; Ulrich Scheler; Jean-Michel Bouler; Bruno Bujoli; Dominique Massiot; Franck Fayon
Journal:  Sci Rep       Date:  2017-08-15       Impact factor: 4.379

Review 3.  Applications of Metals for Bone Regeneration.

Authors:  Kristina Glenske; Phil Donkiewicz; Alexander Köwitsch; Nada Milosevic-Oljaca; Patrick Rider; Sven Rofall; Jörg Franke; Ole Jung; Ralf Smeets; Reinhard Schnettler; Sabine Wenisch; Mike Barbeck
Journal:  Int J Mol Sci       Date:  2018-03-12       Impact factor: 5.923

Review 4.  Gallium containing bioactive materials: A review of anticancer, antibacterial, and osteogenic properties.

Authors:  Fatih Kurtuldu; Nurshen Mutlu; Aldo R Boccaccini; Dušan Galusek
Journal:  Bioact Mater       Date:  2022-01-10

5.  Modifications of Hydroxyapatite by Gallium and Silver Ions-Physicochemical Characterization, Cytotoxicity and Antibacterial Evaluation.

Authors:  Kamil Pajor; Łukasz Pajchel; Anna Zgadzaj; Urszula Piotrowska; Joanna Kolmas
Journal:  Int J Mol Sci       Date:  2020-07-15       Impact factor: 5.923

Review 6.  Cationic Substitutions in Hydroxyapatite: Current Status of the Derived Biofunctional Effects and Their In Vitro Interrogation Methods.

Authors:  Teddy Tite; Adrian-Claudiu Popa; Liliana Marinela Balescu; Iuliana Maria Bogdan; Iuliana Pasuk; José M F Ferreira; George E Stan
Journal:  Materials (Basel)       Date:  2018-10-24       Impact factor: 3.623

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.